BioSpace News Archive

Y2X Life Sciences, a New York-based leader in products that disrupt the transmission of infectious disease, today announced it has entered into an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology that can detect aerosolized SARS-CoV-2.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), hosted its 16th CareKinesis Clinical Advisory Panel (CAP) Meeting, September 9-10, 2021, bringing together Program of All-Inclusive Care for the Elderly (PACE) medical directors from across the country.

Gelteq Pty Ltd, a global leader in ingestible gel technology for healthcare, nutrition and sports, has been granted a U.S. patent (No. 10,983,132) by the U.S. Patent and Trademark Office.

AB Science SA (Euronext - FR0010557264 - AB) today announced that results from masitinib study AB12003 in metastatic castrate refractory prostate cancer, have been presented as a podium presentation at the 2021 American Urological Association (AUA) Annual Meeting by Dr Michel Pavic (Director of the Hematology and Oncology Unit at University of Sherbrooke, Canada).

Enzychem Lifesciences (KOSDAQ: 183490), announced today database lock for the Phase 2 clinical trial of its lead program EC-18 in chemoradiation-induced oral mucositis (CRIOM) had been completed last August.

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2021 Congress.

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of updated data from its partner CStone Pharmaceuticals’ Phase 3 GEMSTONE-302 study at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer (IASLC 2021 WCLC).

Sorrento Therapeutics, Inc., announced that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers.